Regeneron Pharmaceuticals: Osteoarthritis, Knee trials

The registry lists 10 Osteoarthritis, Knee studies with Regeneron Pharmaceuticals as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 6Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the KneeTerminatedNCT03956550Phase 2Results posted
• Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and HipTerminatedNCT03949673Phase 2Results posted
• Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or KneeCompletedNCT03691974Phase 2Results posted
• Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipCompletedNCT03304379Phase 3Results posted
• A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipCompletedNCT03161093Phase 3Results posted
• Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or HipCompletedNCT02683239Phase 3Results posted
• To Assess the Patients' Ability to Self-Administer FasinumabCompletedNCT03491904Phase 1
• Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or HipCompletedNCT02447276Phase 2/3
• A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the KneeWithdrawnNCT01239017Phase 2
• A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the KneeCompletedNCT00944892Phase 1/2